Delcath Systems, Inc. (DCTH)

0.09
0.01 10.51
OTC
Prev Close 0.10
Open 0.09
Day Low/High 0.09 / 0.11
52 Wk Low/High 0.06 / 10.30
Volume 7.50K
Exchange OTC
Shares Outstanding 18.28B
Market Cap 2.01M
Div & Yield N.A. (N.A)

Wall Street Media Presents Exclusive Interview with Dr. Krishna Kandarpa, MD, Ph.D, Chief Medical Officer Of Delcath Systems, Inc.

Wall Street Media presents exclusive video of Dr. Krishna Kandarpa, MD, Ph.

ASCO Live Blog: Sunday

Here are the highlights from the second full day of clinical data presentations at ASCO 2010.

Delcath Liver Tumor Data Improve

Delcath's PHP system delays liver tumor progression by 6.5 months, according to updated results from a phase III study.

ASCO Live Blog: Saturday

The American Society of Clinical Oncology -- ASCO -- annual meeting kicks off today. Here are the highlights.

Biotech Calendar: Key Dates for June

Here's a list of June's potentially stock-moving biotech events.

Keep Cash Levels High

Keep overnight exposures low until the market volatility settles down.

Waiting and Watching

With so much pattern confusion and a total dependency on the overnight markets for guidance, there isn't much to do right now.

Delcath CEO Eamonn Hobbs: Q&A

Delcath Systems CEO Eamonn Hobbs talks to TheStreet about his company's recently released cancer treatment data.

ASCO's Abstract Release Day: Preview

ASCO's Abstract Release Day: Preview

Here's a primer for the American Society of Clinical Oncology's abstract release tomorrow night.

Biotech Stock Mailbag: Immunomedics

Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.

'Mad Money Lightning Round': Sell RIM

Cramer says the stock's done and to sell it.

Cramer's 'Mad Money' Recap: Upside Surprises No Mystery (Final)

Cramer says analysts have been derelict in staying on top of what is happening at companies and updating their estimates during the quarter.

Delcath Liver Tumor System Passes Pivotal Trial Hurdle

Delcath says phase III study exceeds expectations; company will seek FDA approval.

10 Biotech Stocks On the Line

Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.

Biotech Stock Mailbag: Rexahn Pharma

In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.

Delcath Readies Pivotal Trial Results

Delcath will soon release results from a phase III study of its drug-device system to clear tumors from the liver.

10 Biotech Stocks on Clinical Trials Watch

10 Biotech Stocks on Clinical Trials Watch

News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.

Money Solutions, Recovery Stocks, Small Cap Stars

Guests include Christine Benz, author of 30-Minute Money Solutions, Kent Croft, portfolio manager for the Croft Value fund and Marshall Berol, portfolio manager for the Encompass Fund.

Fund Manager Singles Out Hottest Commodity

Fund Manager Singles Out Hottest Commodity

The Encompass Fund, which has doubled in value this year, is staking its fortunes on a spike in uranium prices, driven by demand for nuclear energy.

Delcath Systems Treatment Gets Special FDA Status

Delcath Systems liver cancer drug candidate receives special designation by FDA

Delcath Systems Drug Gets Special FDA Designation

Delcath Systems cancer drug candidate receives additional special designation by FDA

Biotech Mailbag 2008 Review

Here's a look back at the hits, misses and notable moments from 2008.

Biotech Mailbag: NeurogesX Patchy at Best

Biotech Mailbag: NeurogesX Patchy at Best

It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.

Feuerstein's Biotech-Stock Mailbag: Delcath

Feuerstein's Biotech-Stock Mailbag: Delcath

More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.

Biotech Notebook: Xoma, Medivation, Delcath

Biotech Notebook: Xoma, Medivation, Delcath

Xoma's apparent lack of interest in a buyout may not serve investors in the near term.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Delcath rises on regulatory news.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Pointing the finger at the FDA isn't a sound investment strategy.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week: Small-cap stocks garner reader attention.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Bentley Pharmaceuticals rises on a restructuring.

Health Stocks in Motion

Health Stocks in Motion

American Pharmaceutical Partners tumbles on a plan to buy out its parent company.